SynthesisBMC cancer2025
Clinicopathological significance of AKT and phosphorylated AKT expression in hepatocellular carcinoma: A Meta-Analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe implications of AKT and phospho-AKT (p-AKT) expression patterns in various malignancies remain a subject of considerable scientific interest. Current evidence regarding their association with hepatocellular carcinoma (HCC) progression by immunohistochemical (IHC) analyses demonstrates significant inconsistencies.
objectiveThis study aimed to evaluate the clinical significance of AKT and p-AKT expression in HCC patients, with specific emphasis on their correlations with clinicopathological parameters, to provide insights to inform clinical decision-making.
methodWe conducted a systematic literature search across six major electronic databases through February 25, 2024, using search terms related to AKT, p-AKT, IHC, and hepatocellular carcinoma. Eligible studies were selected through strictly screening according to the inclusion/exclusion criteria, with methodological quality assessed via the Newcastle-Ottawa Scale (NOS). Statistical analyses were performed using Stata 15.0 software.
resultA total of 17 eligible publications with a total of 1595 patients were analyzed in the meta-analysis. AKT overexpression in HCC correlated with advanced TNM stage (OR = 3.698, 95% CI = 1.224-11.167), vascular invasion (4.121;1.483-11.447), lymph node metastasis (2.958;1.188-7.367), capsule integrity compromise (2.491;1.192-5.206), and portal vein cancer thrombus (6.919;1.240-38.619). p-AKT expression in HCC demonstrated associations with tumor grade (2.789;1.379-5.641), TNM stage progression (3.058;1.779-5.255), tumor size > 5 cm (2.507;1.056-5.953), portal vein cancer thrombus (4.280;1.798-10.188), and cirrhotic history (1.933;1.226-3.047). For results with significant heterogeneity, we used a random-effects model to pool the effect sizes and conducted subgroup analyses as well as meta-regression analyses. The results indicated that some differences between p-AKT and antibody thresholds were also observed in the subgroup of antibody thresholds, which deserves further research.
conclusionExpression of AKT is associated with TNM stages, venous vascular invasion, metastasis of lymph node, integrity of capsule and portal vein cancer thrombus. And p-AKT expression is associated with histological grades, portal vein cancer thrombus, liver cirrhosis, tumor size and TNM stages. This synthesis establishes AKT as a biomarker for advanced HCC features including metastatic potential and vascular complications, while p-AKT demonstrates dual associations with both tumor progression markers and underlying hepatic pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.